A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
45actual
Sites
20
Countries
Argentina, Bulgaria, Germany +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-09-21 | actual | When the study began enrolling |
| Primary completion | 2026-04-14 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-04-14 | actual | The whole study's end, after follow-up |
| First posted | 2023-08-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-26 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Lupus
Interventions
- Drug: BMS-986326
- Other: Placebo for BMS-986326
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with adverse events (AEs)
measured Up to 228 days
Number of participants with serious adverse events (SAEs)
measured Up to 228 days
Number of participants with clinical laboratory abnormalities
measured Up to 228 days
Number of participants with vital sign abnormalities
measured Up to 228 days
Number of participants with electrocardiogram (ECG) abnormalities
measured Up to 228 days
Number of participants with physical examination abnormalities
measured Up to 228 days
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed